Small molecule · Inhibitor of FMS-like tyrosine kinase 3 (FLT3) · developed by Sunshine Lake Pharma Co.
Clifutinib is an orally bioavailable, selective small molecule inhibitor of FLT3, a receptor tyrosine kinase overexpressed or mutated in acute myeloid leukemia and most B-lineage neoplasms. It binds FLT3 and inhibits its activity, reducing proliferation of FLT3-expressing cancer cells. It is studied in acute myeloid leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05586074 | Phase 3 | Leukemia, Acute Myeloid (AML) | Recruiting | SBFM |
| NCT05133882 | Phase 1/2 | Acute Myeloid Leukemia, Adult | Recruiting | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia, AdultLeukemia, Acute Myeloid (AML)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →